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Lysine acetyltransferases (KATs), p300 (KAT3B), and its close
homologue CREB-binding protein (KAT3A) are probably the
most widely studied KATs with well documented roles in vari-
ous cellular processes. Hence, the dysfunction of p300 may
result in the dysregulation of gene expression leading to the
manifestation of many disorders. The acetyltransferase activity
of p300/CREB-binding protein is therefore considered as a tar-
get for new generation therapeutics.We describe here a natural
compound, plumbagin (RTK1), isolated from Plumbago rosea
root extract, that inhibits histone acetyltransferase activity
potently in vivo. Interestingly, RTK1 specifically inhibits the
p300-mediated acetylation of p53 but not the acetylation by
another acetyltransferase, p300/CREB-binding protein -associ-
ated factor, PCAF, in vivo. RTK1 inhibits p300 histone acetyl-
transferase activity in a noncompetitive manner. Docking stud-
ies and site-directed mutagenesis of the p300 histone
acetyltransferase domain suggest that a single hydroxyl group of
RTK1 makes a hydrogen bond with the lysine 1358 residue of
this domain. In agreement with this, we found that indeed the
hydroxyl group-substituted plumbagin derivatives lost the
acetyltransferase inhibitory activity. This study describes for
the first time the chemical entity (hydroxyl group) required for
the inhibition of acetyltransferase activity.
The eukaryotic genome is organized in a highly complex
nucleoprotein structure, chromatin. Physiologically, chroma-
tin is not just aDNAand histone complex, rather it is a dynamic
organization of DNA associated with histone, histone-interact-
ing non-histone proteins, and RNA (1). The hallmark of chro-
matin is its dynamic nature, which is essential for the regulation
of nuclear processes that require access to genetic information.
This dynamicity of chromatin is maintained by several factors,
including the post-translational modifications of histone and
non-histone chromatin components, especially the reversible
acetylation (2). The enzymatic activity of the acetyltransferases
and deacetylases sets up a fine balance that maintains the cel-
lular homeostasis (3). Any imbalance in this may result in dis-
ease manifestation.
Chromatin acetylation is catalyzed by five different classes of
lysine acetyltransferases (4). Among these, the best studied is
p300 and its close homologue CBP.4 p300 has been shown to
regulate various biological phenomena such as proliferation,
cell cycle regulation, apoptosis, differentiation, and DNA dam-
age response (5–8). It is a potent transcriptional coactivator.
Therefore, dysfunction of p300 may have deleterious effects on
various cellular functions and thus could be the underlying
cause of several diseases, especially cancer. Acetyltransferase
activity has been considered as a target for new generation ther-
apeutics (3, 9). The therapeutic potential of HAT inhibitors has
been shown in cancer (10–12), cardiac diseases (13), diabetes
mellitus (14), and human immunodeficiency virus (15).
Unlike the histone deacetylase inhibitors, the acetyltrans-
ferase inhibitors are relatively fewer in number. Recently, how-
ever, a few potent as well as specific KAT inhibitors have been
discovered (Table 1). Among these, curcumin was found to be
the only known p300-specific natural inhibitor, which is also
cell-permeable (16). Therefore, there is an active ongoing effort
to identify modulators (activator/inhibitor) targeted toward
p300 activity. Here we report that plumbagin, a hydroxynaph-
thoquinone (Fig. 1A) isolated from the roots of Plumbago rosea
(known in Indian ayurvedic medicine as Chitraka), is a potent
acetyltransferase inhibitor in vivo. Most of the known KAT
inhibitors, possess polyhydroxy functional groups, whereas
plumbagin has a single hydroxyl group. The substitution of this
group with other moieties resulted in a complete loss of the
p300 inhibitory activity. Therefore, these data for the first time
establish the chemical entity (functional group) responsible for
p300 inhibition.
MATERIALS ANDMETHODS
Isolation and Purification of Plumbagin from P. rosea Roots
The dried and powdered roots of P. rosea (100 g) were
extracted with ethyl acetate. The ethyl acetate extract after
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removal of the solvent under reduced pressure gave a dark
brown semisolid, which was separated into phenolic and neu-
tral fractions by treatmentwith 5%NaOHand followed by acid-
ification with 2 M HCl and extraction with diethyl ether. The
phenolic fractionwas subjected to flash chromatography (230–
400 mesh) using increasing polarity. The fraction extracted
with 4% ethyl acetate in hexane mixture gave an orange solid,
which on further recrystallization yielded plumbagin/RTK1
(0.286 g). The yielded compound was compared with commer-
cially available material.
Immunoblotting Analysis
HepG2 cells (1.5  106 cells per 60-mm dish) were seeded
overnight, and histones were extracted by acid extraction after
12 h of treatment with increasing concentrations of plumbagin.
Immunoblotting analysis was performed as described else-
where (17), using polyclonal acetylated histone H3 and poly-
clonal histone H3 antibodies.
Immunofluorescence Analysis
To visualize the inhibition of histone acetylation in vivo,
HeLa cells were cultured as a monolayer on the poly-L-lysine-
coated coverslips in Dulbecco’s modified Eagle’s medium
(Sigma). Immunofluorescence was carried out as described
elsewhere (17). Fixed cells were probed with anti-acetylated
histone H3 polyclonal antibodies followed by secondary anti-
body conjugatedwithAlexa 488 (Invitrogen). To stain the chro-
mosomal DNA, Hoechst 33528 (Sigma) was used. The images
were taken by using Zeiss LSM 510 laser scanning confocal
microscope.
Immunohistochemical Analysis of Mice Liver on Plumbagin
Treatment
Plumbagin (25 mg/kg body weight) dissolved in 50 l of
DMSO was injected intraperitoneally to 2-month-old Swiss
albino mice. As controls, two mice were injected with 50 l of
water and 50 l of DMSO intraperitoneally as negative control
and solvent control, respectively. The experiment was done in
triplicate. All mice were staged in animal cages for the next 6 h
and anesthetized, and the liverwas collected for further protein,
RNA, and immunohistochemical analysis.
Liver samples stored in formalin were further dehydrated in
alcohol, followed by xylene treatment, and allowed to get
impregnated in paraffin blocks. 3–4-m thick paraffin-embed-
ded sections were deparaffinized in xylene, followed by rehy-
dration in decreasing concentrations of ethanol solutions. For
routine pathological examination, deparaffinized sections from
all blocks were stainedwith hematoxylin and eosin stains. Anti-
gen retrieval was performed by microwaving in appropriate
buffer. After washing the sections in 0.1 M phosphate buffer,
blockingwas done using 3% skimmedmilk, followingwhich the
sections were incubated with anti-AcH3 antibody for 3 h in a
humidification chamber. After 0.1 M phosphate buffer wash,
the sections were incubated with link secondary antibody
(DAKO LSAB) for 3 h in a humidification chamber. After
washing, the sections were developedwith 3,3-diaminobenzi-
dine tetrahydrochloride (Sigma). Hematoxylin was used as
counterstain to identify the unstained nucleus.
p53Modulation Assays
HEK293 cells were incubated for 3 h with 2.5, 5, and 10 M
plumbagin. After the compound treatment, the cells were
treated with 500 ng/ml doxorubicin for 6 h. The cells were then
harvested and lysed in TNN buffer (150 mM NaCl, 50 mM Tris,
pH 7.4, 1% Nonidet P-40, 0.1% sodium deoxycholate, 1 mM
EDTA, 0.5g/ml leupeptin, 0.5g/ml aprotinin, and 0.5g/ml
pepstatin) for 3 h on ice with intermittent mixing. The whole
cell lysates from the treated cells were subjected to Western
blotting analysis by using mouse monoclonal anti-p53 anti-
body, DO1 (Calbiochem), rabbit polyclonal acetylated p53 Lys-
373, and Lys-320 antibodies (Upstate) and tubulin antibody
(Calbiochem).
Histone Acetyltransferase Assay
HAT assays were performed as described previously (17). 2.4
g of highly purified HeLa core histones were incubated in
HAT assay buffer at 30 °C for 10 min with or without baculovi-
rus-expressed recombinant p300 or PCAF in the presence and
absence of compounds followed by addition of 1.0 l of 3.6
Ci/mmol of [3H]acetyl-CoA (PerkinElmer Life Sciences) and
further incubated for another 10 min in a 30-l reaction. The
reaction mixture was then blotted onto P81 (Whatman) filter
paper, and radioactive counts were recorded on a Wallac 1409
liquid scintillation counter.
ProteinMethyltransferase Assay
2.4 g of highly purified HeLa core histones along with
CARM1 (20 ng)/G9a (15 ng) were incubated in the buffer con-
taining 20 mM Tris, pH 8.0, 4 mM EDTA, pH 8.0, 200 mMNaCl,
and 1 l of 15 Ci/mmol of S-[3H]adenosylmethionine (Amer-
sham Biosciences), either in the presence or absence of com-
pound in a final reaction volume of 30 l at 30 °C for 30 min.
The reaction was stopped on ice for 5 min before blotting onto
P81 (Whatman) filter paper. The radioactive counts were
recorded on Wallac 1409 Liquid Scintillation counter.
p300 HATDomain Purification
The recombinant minimal HAT domain was purified as
described elsewhere (18).
Kinetic Characterization of RTK1-mediated p300 Inhibition
The HAT reactions were carried out with the baculovirus-
expressed recombinant full-length p300, in the presence of dif-
ferent concentrations of the inhibitor RTK1 (15, 20, 35, and 45
M). The HAT reaction consists of two substrates, core his-
TABLE 1
HAT inhibitors
Serial No. HAT inhibitor Target Ref.
1 Lysyl-CoA p300 34
2 H3-CoA-20 PCAF 34
3 Anacardic acid p300/PCAF/CBP 30
4 Garcinol p300/PCAF/CBP 16
5 Curcumin p300/CBP 16
6 -Butyrolactones CBP/Gcn5 35
7 Isothiazolones p300/PCAF 11
8 LTK14 p300 17
9 Epigallocatechin 3-gallate HATs 29
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tones and the acetyl group donor [3H]acetyl-CoA. Therefore,
the kinetic analysis was done in two different sets. In the first
set, concentration of core histones was kept constant at 1.6M,
and [3H]acetyl-CoA was varied from 1.08 to 8.66 M. In the
second assay, [3H]acetyl-CoAwas kept constant at 2.78M, and
core histones were varied from 0.003 to 0.068 M. The incor-
poration of the radioactivity was taken as ameasure of the reac-
tion velocity recorded as counts/min. Each experimentwas per-
formed in triplicate, and the reproducibility was found to be
within 15% of the error range. Weighted averages of the values
obtained were plotted as a Lineweaver-Burk plot using Graph-
Pad Prism software.
Isothermal Titration Calorimetry (ITC)
ITC experiments were carried out in a VP-ITC system (Micro-
cal LLC) at 25 °C. Samples were centrifuged and degassed prior to
titration. Titration of RTK1/RTK2 against the protein HAT
domain was carried out by injecting 0.2 mM RTK1/RTK2 in 20
mM Tris, pH 7.5, 0.2 mM EDTA, 100 mM KCl buffer against
0.0034 mM HAT domain. A 2-min interval was allowed
between injections for equilibration. A total of 40 injectionswas
carried out to ensure complete titration. The protein concen-
tration was chosen to achieve sufficiently high heat signals with
a minimum enthalpy of dilution. To minimize the error associ-
ated with diffusion from the syringe during base-line equilibra-
tion, the first injection was only 1 l, and the associated small
heat change was not considered for data analysis. Blank titra-
tions were carried out using buffer and DMSO with no ligand
against the HAT domain and used for subtraction of the back-
ground heat change. The corrected heat changes were plotted
against the molar ratio of the titrated products and analyzed
using the manufacturer’s software, which yielded the stoichi-
ometry n (in terms of number of molecules of RTK1/protein),
equilibrium constant (Ka). From the relationship G0  RT
ln Ka and the Gibbs-Helmholtz equation, the free energy of
binding and the entropy of association (S0) were calculated.
Docking Studies
Crystal structure of p300 HAT domain was extracted from
Protein Data Bank code 3BIY. Crystal structure of the inhibitor
RTK1 and its inactive derivative RTK2was obtained and solved
(Bruker X8 APEX). The HAT domain was docked with the
structure of RTK1 and RTK2 to find out their interaction sites
on HAT domain. RTK1 has a hydroxyl group at the 5th carbon
position, and the derivative RTK2 has a methoxy group instead
of the hydroxyl group.
Molecular simulation and the docking of HAT domain with
RTK1 and RTK2 were performed using Hex 4.5 software. The
docking calculations were done using three-dimensional para-
metric functions of both the protein (HAT domain) and the
chemical structures (RTK1/RTK2). These calculations were
used to encode surface shape and electrostatic charge and
potential distributions. The parametric functions are based on
expansions of real orthogonal spherical polar basis functions.
The docking was performed in full rotationmode; both domain
and inhibitor were taken at 180 ranges for 20,000 solutions.
Site-directedMutagenesis
Site-directedmutagenesis was done to obtain aHATdomain
point mutant K1358A. HAT domain expression clone in
pET28b was used as the template, and the mutagenesis was
done by the Stratagene site-directed mutagenesis kit according
to the manufacturer’s instructions. The positive clones were
sequenced and transformed into BL21 strain ofEscherichia coli.
The expression and purification of the mutant protein was
done as mentioned elsewhere (18).
General Methods
NMR spectroscopy, TLC, and x-ray characterization of the
compounds were done as described elsewhere (17). High reso-
lution mass spectrometry was obtained on a Bruker Daltonics
APEX II (for electrospray ionization).
Synthesis of Plumbagin/RTK1 Derivatives
RTK2, 5-Methoxy-2-methyl-1,4-naphthoquinone—The solu-
tion of RTK1 (100 mg, 0.53 mmol) in acetone, anhydrous potas-
sium carbonate (146 mg, 1 mmol) was stirred for about 10 min,
andthenmethyl iodide (43mg,0.3mmol)wasaddeddropwiseand
the stirring continued for about 2 h. The reaction was monitored
by TLC. Then solvent was evaporated to dryness and subjected to
column chromatography, which yielded the compound RTK2.
RTK3, 5-Ethoxy-2-methyl-1,4-naphthoquinone—Ethyl iodide
(55mg, 0.35mmol) was added dropwise to the solutionmixture
of RTK1 (100 mg, 0.53 mmol) and anhydrous potassium car-
bonate (146 mg, 1 mmol) in acetone for about 20 min, and the
reaction mixture was stirred for 2 h. The solvent was evapo-
rated to dryness and subjected to CC to yield RTK3.
RTK4, 5-Isopropoxy-2-methyl-1,4-naphthoquinone—The mix-
ture of RTK1 (100 mg, 0.53 mmol) and anhydrous potassium
carbonate (146mg, 1mmol) in acetone was stirred for about 10
min in a two-necked round bottom flask. Isopropyl iodide (63
mg, 0.37mmol) was then added dropwise, and stirringwas con-
tinued for another 2 h. The solvent was evaporated under
reduced pressure and subjected to CC to yield compound
RTK4.
RTK5, 6-Methyl-5,8-dioxo-5,8-dihydronaphthalen-1-yl
Acetate—A solution of RTK1 (100 mg, 0.53 mmol) in dichlo-
romethanewas added to a cooled solution of triethylamine (148
mg, 1.4 mmol) in dichloromethane. The reaction mixture was
stirred for 30 min at 0–5 °C, and then acetyl chloride (56 mg,
0.71 mmol) was slowly added into the reaction mixture for a
period of 30 min. After stirring at 0–5 °C for 6 h, the tempera-
ture was slowly increased to 20–25 °C and again stirred for 4 h.
The solvent was evaporated to dryness and purified by CC
resulting in compound RTK5.
RTK6, 6-Methyl-5,8-dioxo-5,8-dihydronaphthalen-1-yl
Methanesulfonate—RTK1 (100 mg, 0.53 mmol) was dissolved
in dichloromethane (10ml). Triethylamine (148mg, 1.4 mmol)
was added, and the reaction mixture was cooled to 0–5 °C.
Methylsulfonyl chloride was slowly added (61mg, 0.538mmol)
in dichloromethane. The reactionmixture was stirred for 4 h at
0–5 °C, and the temperature was raised slowly to 20–25 °C and
stirred for 8–10 h. The resulting reaction mixture was isolated
and subjected to CC to yield RTK6.
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RTK7, 2-Methyl-5-(2-piperidin-1-ylethoxy)-1,4-naphtho-
quinone—RTK1 solution (100 mg, 0.53 mmol) in ethanol (20
ml), potassium hydroxide (59 mg, 1 mmol) was taken in a
round bottom flask and stirred for about 10 min, followed by
addition of 1-(2-chloroethyl)piperidine hydrochloride (117
mg, 0.63 mmol), and the reaction mixture was heated to
60 °C. After 2 h, the reaction mixture was cooled to room
temperature, poured into water, acidified with dilute HCl,
and extracted with ethyl acetate. The extract was evaporated
to get residue, which was subjected to CC to get RTK7.
RTK8, 2-Methyl-5-(2-morpholin-4-ylethoxy)-1,4-naph-
thoquinone—The 4-(2-chloroethyl)morpholine hydrochlo-
ride (118 mg, 0.63 mmol) was added into the reaction mix-
ture of RTK1 (100 mg, 0.53 mmol) and potassium hydroxide
(59 mg, 1 mmol) in ethanol. The
reaction mixture was heated up to
60 °C over a period of 90 min fol-
lowed by cooling. The mixture was
poured into ice-cold water and
acidified with dilute HCl to pH 7.0
and extracted with ethyl acetate.
The extract was evaporated to get
residue and subjected to CC to
yield RTK8.
RTK9, Ethyl [(6-Methyl-5,8-di-
oxo-5,8-dihydronaphthalen-1-yl)-
oxy]acetate—The solution of
RTK1 in acetone (100 mg, 0.53
mmol) and potassium carbonate
(146 mg, 1 mmol) was stirred at
room temperature for about 10
min followed by addition of ethyl
bromoacetate (76 mg, 0.46 mmol),
and the temperature was slowly
increased to 50 °C. The reaction
mixture was heated for about 2 h
and poured into ice and acidified
with dilute HCl (to pH 7) and then
extracted with ethyl acetate. The
extract was evaporated to get resi-
due, which was subjected to CC to
get RTK9.
RTK10, 5-[2-(Dimethylamino)-
ethoxy]-2-methyl-1,4-naphthoqui-
none—RTK1 solution (100 mg,
0.53 mmol) in ethanol, potassium
hydroxide (59 mg, 1 mmol) were
taken in a two-necked round bot-
tom flask, stirred for about 10 min,
followed by addition of 2-chloro-
N,N-dimethylethanamine (92 mg,
0.63 mmol), and the reaction mix-
ture was heated to 60 °C. After 2 h,
the reaction mixture was cooled
to room temperature, poured in
water, and extracted with ethyl
acetate. The extract was evapo-
rated to get residue, which was
subjected to CC to get compound RTK10.
RESULTS ANDDISCUSSION
The dysfunction of lysine acetyltransferases could be associ-
ated with several diseases, like asthma, cardiovascular disor-
ders, diabetes, and cancer (10–15). We have established a
screening system of medicinal plants (described in the Indian
ayurvedic literature, see Ref. 36), for acetyltransferase modula-
tion activity. In this process, we have tested the crude extract of
P. rosea and eventually isolated plumbagin (RTK1) and crystal-
lized to characterize the compound (Fig. 1A, panel II).
Plumbagin/RTK1 Inhibits in Vivo Histone Acetylation—
RTK1 is a highly cell-permeable compoundwith important cel-
lular effects like anti-tumor activity (19–22), NF-B activity,
FIGURE 1. RTK1 is a potent inhibitor of histone acetylation in vivo. A, panel I, ball and stick model of RTK1,
where blue denotes carbon; white indicates hydrogen; and red represents oxygen; panel II, x-ray crystal struc-
ture of RTK1 is shown. B,HepG2 cells were treated as indicated for 12 h; histones were isolated from untreated
cells (lane 1). DMSO-treated cells (lane 2), RTK1-treated cells (lanes 3–5). The histone acetylationwas probed by
immunoblotting using acetylated H3 antibody. As a loading control the blots were probed with histone H3
antibody. C, inhibition of histone acetylation was visualized by immunofluorescence analysis of RTK1-treated
HeLa cells probedwith antibodies against acetylated histone H3. The Hoechst-stained images represent DNA.
Cells were either treated with DMSO or with RTK1 (10 M and 25 M) in the presence of trichostatin A and
sodium butyrate (TSA/NaBu) as indicated for 12 h.D, liver tissue frommice injected with water (panel I), DMSO
(panel II), and RTK1 (panel III) was stainedwith hematoxylin and eosin (H&E) or immunostainedwith antiacety-
lated histone H3 antibody as indicated.
Plumbagin Is a KAT Inhibitor
24456 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 284•NUMBER 36•SEPTEMBER 4, 2009
 by guest, on O
ctober 27, 2010
w
w
w
.jbc.org
D
ow
nloaded from
 
etc. (23). RTK1 is a potent apoptosis-inducing agent at higher
concentrations. Histones (both H3 and H4) are known to be
hyperacetylated in hepatocarcinomas (24). To find out the abil-
ity of RTK1 to inhibit HAT activity in vivo, the liver cancer cell
line HepG2 was treated with RTK1 at concentrations that do
not induce apoptosis. In agreement with a previous report (24),
the histone H3was found to be substantially acetylated in these
cells (Fig. 1B, lane 1). The acetylated histone H3 level was
reduced by 50% with 5 M RTK1 treatment (Fig. 1B, lane 2). A
dose-dependent inhibition of histone H3 acetylation was
observedwith almost 90% inhibition on 25MRTK1 treatment
(Fig. 1B, lane 4). The overall acetylation status of the histones
was also found to be significantly decreased with a prominent
reduction of H3 and H4 acetylation (supplemental Fig. 1).
Because the HepG2 cells grow in clumps, the immunofluores-
cence imaging of these cells was difficult. Therefore, the histone
acetylation upon plumbagin treatment was verified by immu-
nofluorescence analysis in HeLa cells, wherein the cells were
treated with the compound and DMSO (solvent control) for
12 h. Because the acetylation level in HeLa cells is low, histone
acetylation was induced by treating with histone deacetylase
inhibitors (Fig. 1C, TSA/NaBu) followed by RTK1 treatment.
As expected, RTK1 could inhibit the histone acetylation in
HeLa cells efficiently at 5 M concentration. There was an
almost complete reduction in the acetylation levels with 25 M
concentration of RTK1, as visualized by immunofluorescence
analysis (Fig. 1C, DMSO versus RTK1). Furthermore, the HAT
inhibition by RTK1was also confirmed in vivowherein the liver
tissue of RTK1-treated mice was examined for inhibition of
histone acetylation. As visualized by immunohistochemistry
using antibody against acetylated histone H3 (Lys-9 and Lys-
14), there was a significant decrease in histone acetylation in
RTK1-treated mice liver as compared with the normal and
DMSO-treated controls. The acetylation status of histones in
the untreated mouse liver was taken as the control for compar-
ing the treated sections (Fig. 1D, panel I, H&E staining and
AcH3 staining). There was no gross loss in morphology of cells
as indicated by the hematoxylin and eosin staining. The solvent
control sections show strong to moderate positive staining in
hepatocytes near the central vein and portal triad regions indi-
cating the ability of the solvent for inducing the acetylation in
these cells (Fig. 1D, panel II, H&E staining and AcH3 staining).
On the other hand, RTK1dissolved in theDMSOsolvent shows
negative staining for Ac-H3 antibody indicating the inhibitory
activity of acetylation by RTK1 in this liver sample (Fig. 1D,
panel III of H&E staining and AcH3 staining). Taken together,
these data suggest that RTK1 inhibits histone acetylation
in vivo.
Plumbagin/RTK1 Inhibits Non-histone Protein Acetylation
by p300—The inhibition of histone acetylation by plumbagin
was investigated by an antibody raised against the peptide
resembling the histone H3 tail, in which the Lys-9 and Lys-14
residues are acetylated. In vivo, these residues are acetylated by
HATs p300/CBP and PCAF, which are also referred to as factor
acetyltransferases or protein acetyltransferases. This is because
of their ability to act on several non-histone substrates leading
to distinct functional consequences. p53 is an in vivo substrate
of both these histone acetyltransferases. p300 and PCAF acet-
ylate different lysine residues (Lys-373 and Lys-320, respec-
tively) of p53 upon DNA damage (25). To investigate any pos-
sible specificity of RTK1 to KAT activity in the cellular system,
we selected the phenomenon of p53 acetylation. For this pur-
pose, we treated HEK293 cells with different concentrations of
RTK1 for 3 h following which acetylation of p53 was enhanced
by treating cells with doxorubicin for 6 h. Whole cell lysates
prepared from the treated cells (as described above) were sub-
jected to Western blotting analysis using antibodies against
p53, acetyl-p53 (Lys-373), acetyl-p53 (Lys-320), and -tubulin.
It was found that the acetylation of p53 at lysine 373 (by p300)
was inhibited by treating cells with increasing concentrations of
RTK1 (Fig. 2, panel II, lane 1 versus lanes 2–4). Significantly,
similar concentration of RTK1 did not affect the acetylation of
p53 at lysine 320 (by PCAF) (Fig. 2, panel III, lane 1 versus lanes
2–4). Levels of p53 and tubulin were used as protein expression
controls (Fig. 2, panels I and IV). Yet another non-histone sub-
strate of p300 is positive cofactor 4 (PC4),whose transcriptional
coactivator function on p53 is controlled by its acetylation (26).
The in vitro acetylation of PC4 by p300 was found to be inhib-
ited by RTK1 in a gel fluorography assay (supplemental Fig. 2).
These results establish that indeed RTK1 preferentially targets
p300-mediated lysine acetyltransferase activity in the physio-
logical context. Significantly, the treatment of RTK1 in the
HepG2 cells did not alter the expression of p300 (data not
shown), suggesting that it is the enzymatic activity that is mod-
ulated and not the protein expression.
Plumbagin/RTK1 Is a p300 HAT Inhibitor—RTK1 could
inhibit the histone and non-histone protein acetylation in vivo
with a specificity toward p300. We further investigated the
comparative HAT inhibition activity of RTK1 and other known
inhibitors such as anacardic acid, garcinol, isogarcinol, LTK14,
and curcumin (Fig. 3B). The IC50 value of RTK1 with the full-
length p300 (supplemental Fig. 3) was found to be similar to
that of other p300-specific inhibitors, LTK14 and curcumin
FIGURE 2. RTK1 inhibits p300-mediated non-histone protein acetyla-
tion.HEK293 cells were treated with either DMSO (lane 1) or RTK1with the
indicated concentrations (lanes 2–4) for 3 h. Following the treatment, the
cells were treated with doxorubicin for 6 h. The cell lysates were subjected
to immunoblotting analysis using either anti-acetyl-p53 Lys-373 (-Acp53
(K373), panel II) or anti-acetyl-p53 Lys-320 (-Acp53 (K320), panel III), or
anti-p53 DO-1 (panel I), or anti-tubulin (panel IV). Tubulin and p53 anti-
body were used to verify the equal amounts of protein loaded into each
lane.
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FIGURE 3. RTK1 is an inhibitor of histone acetyltransferase p300. A, filter binding HAT assay for inhibition of histone acetylation. Assays were performed with
hexahistidine-tagged, baculovirus-expressed full-length p300 in the presence or absence of HAT inhibitors at their reported IC50 concentrations by using highly
purified HeLa core histones. The following core histones are shown: without p300 (lane 1); with p300 (lane 2); with p300 in the presence of DMSO (lane 3); in the
presence of anacardic acid (10M) (lane 4); in the presence of garcinol (10M) (lane 5); in the presence of isogarcinol (10M) (lane 6); in the presence of curcumin (25
M) (lane 7); in thepresenceof LTK14 (20M) (lane 8); and in thepresenceof RTK1 (25M) (lane 9). Error bars represent S.D.B, chemical structures of theHAT inhibitors
are in the following order: anacardic acid (4); garcinol (5); isogarcinol (6); curcumin (7); LTK14 (8); and RTK1 (9). C, HAT assay was performed with FLAG-tagged
baculovirus-expressed PCAF in the presence or absence of RTK1 by using highly purified human (HeLa) core histones and processed for filter binding assay. Core
histones are as follows: without enzyme (lane 1); with enzyme (lane 2); with enzyme in the presence of DMSO (lane 3); with enzyme in the presence of increasing
concentrationof RTK1, 10, 25, and50M (lanes 4–6). Error bars represent S.D.D, filter bindingassay for inhibitionofhistone (arginineand lysine)methylation.Histone
methylationassayswereperformedeitherwithCARM1 (I) orG9a (II) in thepresenceor absenceof RTK1byusinghighlypurifiedHeLa corehistones andprocessed for
filter binding assay. Core histones are as follows: without enzyme (lane 1); histones with enzyme (lane 2); histones with enzyme in the presence of DMSO (lane 3);
histoneswith enzyme in the presence of increasing concentrations of RTK1, 10, 25, 50, and 100M. Error bars represent S.D.
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(20–25M) (Fig. 3A, lanes 7–9). However, in vitro, it could also
inhibit the lysine acetyltransferase PCAF at a higher concentra-
tion with an IC50 beyond 50 M (Fig. 3C, lanes, 4–6). To
address the broad spectrum specificity of RTK1 among differ-
ent chromatin-modifying enzymes, the effect of RTK1 on lysine
and arginine methyltransferase activity was also investigated.
The results show that even at 100Mconcentration it could not
inhibit the methyltransferase activity of G9a (lysine methyl-
transferase) and CARM1 (arginine methylation) (Fig. 3D, lanes
4–7). Taken together, these data suggest that RTK1, isolated
from a natural source, is an inhibitor of histone acetyltrans-
ferases with a preference toward p300.
Plumbagin/RTK1 Is a Noncompetitive Inhibitor of p300 HAT
with a Single Binding Site on the Protein—To understand the
mechanism of RTK1-mediated inhibition of p300 activity, the
enzyme inhibition kinetic analysis was performed. The kinetic
analysis of the RTK1-mediated inhibition of p300 acetyltrans-
ferase revealed a noncompetitive pattern with both histones
FIGURE 4. RTK1 is a noncompetitive inhibitor of p300 acetyltransferase activity with a single binding site. A and B, kinetics of p300 HAT inhibition by
RTK1.A, Lineweaver-Burk Plot representationof RTK1-mediated inhibitionof p300HATactivity at a fixed concentrationof corehistones (1.6M) and increasing
concentrations of [3H]acetyl-CoA in the presence (15, 20, 35, and 45 M) or absence of RTK1. B, Lineweaver-Burk plot representation of RTK1-mediated
inhibition of p300 HAT activity at a fixed concentration of [3H]acetyl-CoA (2.78M) and increasing concentrations of core histones in the presence (15, 20, 35,
and 45 M) or absence of RTK1. The results were plotted using the GraphPad Prism software. C, domains of histone acetyltransferase p300. Apart from the
minimal HAT domain (1284–1673), three CH domains, a single bromodomain, and the KIX domain are present. D, percentage of inhibition of HAT activity,
performedwithp300minimalHATdomain in thepresenceor absenceof RTK1 (0.5–100M), byusinghighlypurifiedHeLa corehistones andprocessed for filter
binding assay. E, determination of enthalpy of association of RTK1 with p300 HAT domain. The exothermic heat exchanged per mol of injectant as a function
of molar ratio of HAT domain to RTK1. The data were fitted with “one set of sites” binding model. Solid line represents the fit of the binding isotherm.
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and acetyl-CoA substrates (Fig. 4, A and B). The mechanism of
inhibition therefore involves the inhibitor binding to a site
other than the active site of the enzyme, which was subse-
quently confirmed by docking studies and also isothermal titra-
tion calorimetry.
The baculovirus-expressed full-length p300 often gets
degraded and may also contain some interacting proteins even
after high quality purification. Because the biophysical experi-
ments require proteins that are highly pure, the subsequent
experiments were carried out with the bacterially expressed
p300 minimal HAT domain (amino acids 1284–1673). RTK1
inhibits theHATactivity of the p300 catalytically active domain
with a very low IC50 value of 2 M indicating the possible inter-
action of RTK1 with this domain (Fig. 4D). RTK1 could inhibit
the minimal HAT domain more potently than the full-length
p300. There was a reduction in the IC50 value (2 M) for the
HAT domain that is 10-fold lower than the IC50 value (20 M)
of full-length p300. However, the pattern of HAT inhibition
was similar to that of p300 full-length, i.e. noncompetitive in
nature (supplemental Fig. 4). These results further suggest that
RTK1 augments its p300 HAT inhibitory activity by directly
targeting the minimal HAT domain of p300, which consists of
the region responsible for acetyltransferase activity. Further-
more, it should be noted that full-length p300 has the CH1,
CH2, CH3, bromodomain, repressive KIX domain, and the
unstructured glutamine-rich region (Fig. 4C) (18). The site of
interaction of RTK1 may not be easily accessible in the full-
length protein because of its multidomain organization. How-
ever, in theminimal HAT domain, the interaction sitemight be
easily accessible, which could be the cause of reduction in the
IC50 value. In agreement with this data, it has been shown that
the p300-specific inhibitor LTK14 also has a 10 times lower
IC50 value with the HAT domain than the full-length enzyme
(27).
The binding of the inhibitor to the enzyme was also con-
firmed from isothermal titration calorimetry studies (Fig. 4E).
FIGURE 5. K1358A residue of p300 HAT domain is essential for RTK1 interaction. A, docking of RTK1 onto the p300 HAT domain (panel I) and enlarged
image of the docking site with the contact residues (panel II). B, docking of RTK1 onto the in silico generated mutant K1358A. C, filter binding HAT assay for
histoneacetylation.Assayswereperformedwithp300HATdomain (HDwt (wild type)) orHATdomainK1358AbyusinghighlypurifiedHeLa corehistones. Core
histonesare shownas follows:withoutenzyme (lane1);withHATdomainwild type (lane2);withHATdomainK1358A (lane3); andwith increasedconcentration
of HAT domain K1358A (lane 4). Error bars represent S.D.
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The interactionwas found to be entropy-drivenwith high affin-
ity (Kd 2 0.25M,H2.25 0.23 kcal/mol,S 17.2
entropy units). The binding isotherm could be fitted to a 1:1
stoichiometry. The magnitude of the enthalpy value is consist-
ent with the range of enthalpy values reported for a hydrogen
bond such as the one proposed between the RTK1 and p300
HAT domain. The source of positive entropy may be 2-fold as
follows: release of bound water from the surface of the protein
upon association with the ligand and conformational entropy
change of the protein as a sequel to binding. From the above
observations, it can be proposed that RTK1 binds to the HAT
domain at a single site that is not a part of the active site. The
dissociation constant value agrees well with the IC50 value (2
M) as estimated from Fig. 4D, thereby supporting the validity
of the thermodynamic parameters generated from ITC.
Plumbagin/RTK1Docks onto the p300 HATDomain through
Hydrogen Bonding to Lys-1358 Residue with Functional
Consequences—The crystal structure of the acetyltransferase
domain of p300 liganded to a synthetic specific inhibitor, lysyl-
CoA (28), has been reported recently. Using this structure, the
docking studies with RTK1 have been performed. The p300
HAT domain and inhibitor complex showed an interaction
with the hydroxyl group on the 5th carbon in RTK1. The resi-
dues involved in the interaction are Lys-1358, Glu-1380, Met-
1376, and Tyr-1421 (Fig. 5A, panel I, and supplemental Fig. 5).
As per the docking model, theOOH group interacts with Lys-
1358 on the HAT domain and facilitates the further interaction
with the remaining three residues (Fig. 5A, panel II). Because
the lysine residue was found to be the primary residue mediat-
ing the interaction and the ITC data also suggested a single
binding site, this residue (Lys-1358) wasmutated to alanine. An
in silico mutant K1358A was generated that did not show any
interaction with the inhibitor (Fig. 5B). Subsequently, the same
mutantwas cloned and expressed. ThemutantK1358A showed
a similar tryptophan fluorescence spectra as the wild type, sug-
gesting that the overall protein structure was not altered due to
the mutation (supplemental Fig. 6, A and B). Remarkably, this
lysine residue was found to be absolutely critical for the HAT
activity. It was found that the HAT domain mutant (K1358A)
completely lost its acetyltransferase activity in a filter binding
assay (Fig. 5C). The small molecule inhibitor RTK1 through its
hydroxyl group possibly forms a specific interaction with a sin-
gle lysine residue (Lys-1358) in the p300 HAT domain. The
Lys-1358 residue is not a part of the activation loop of p300 and
has not beenmapped as an important residue in the p300 HAT
domain structure. However, one of its adjacent residues, Thr-
SCHEME 1. Synthesis scheme and structures of RTK1 and its derivatives (a–i).
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1357, has been shown to be essential for the structural mainte-
nance of theHAT domain (28). The Thr-1357 residue is a com-
ponent of the negative environment chamber for the activation
loop. Presumably, the Lys-1358 residue also plays an essential
role in the activation loop stability directly and/or by affecting
the chemical environment around the Thr-1357 residue and
hence the acetyltransferase function.
Single Hydroxyl Group of Plumbagin/RTK1 Is Essential for
HAT Inhibition—The docking study and the point mutation of
K1358A indicated that the single hydroxyl group of RTK1 is
possibly involved in interacting with the HAT domain. There-
fore, we investigated the chemical entity in “RTK1,” which
could be involved in the inhibition of p300 HAT activity. RTK1
was derivatized by using the single hydroxyl group at 5th car-
bon position with various substituents (Scheme 1). Alkyl sub-
stitutions at the OOH position, which increased the chain
length, could not inhibit HAT activity (Fig. 6A, lanes 5–7).
When groups like acetyl and sulfonyl were substituted for the
hydroxyl group of RTK1, a mild reduction (10%) of HAT
activity was observed (Fig. 6A, lanes 8 and 9). Heterocyclic sub-
stitutions such as piperidine, morpholine, and an ester substi-
tution also showed a mild reduction of HAT activity (Fig. 6A,
FIGURE 6. Single hydroxyl group of RTK1 is essential to inhibit p300HAT activity. A,HAT assays were performed either with p300 (see I) or PCAF (see II) in
the presence or absence of RTK1 and its derivatives by using highly purified HeLa core histones. Core histones are shown as follows: without enzyme (lane 1);
with enzyme (lane 2); with enzyme in the presence of DMSO (lane 3); RTK1 (25 M) (lane 4), RTK2-RTK10 (Scheme 1) at 50 M concentration (lanes 5–13,
respectively). Error bars represent S.D. B, panel I, ball and stickmodel of RTK2. where bluedenotes carbon,white indicates hydrogen, and red represents oxygen;
panel II, x-ray crystal structure of RTK2, hydroxyl group substituted bymethoxy group. C, estimation of enthalpy of association of RTK2with p300 HAT domain.
The exothermic heat exchanged per mol of injectant as a function of molar ratio of HAT domain to RTK2. The data could not be fitted with any bindingmodel
giving rational values for enthalpy change and dissociations constant. It implies absence of association. D, docking of RTK2 onto the p300 HAT domain.
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lanes 10–12). However, N,N-dimethylamine substituent did
not affect theHAT activity (Fig. 6A, lane 13). As comparedwith
RTK1, all the derivatives were inactive for HAT inhibition at
the tested concentration. Thus, the substitution of the hydroxyl
group with any other group almost abolishes the inhibition
activity, suggesting that the “hydroxyl” group in RTK1 is essen-
tial to bring about the HAT inhibition (Fig. 6A, lane 4 versus
lanes 5–13). One of the derivatives, RTK2 (Fig. 6B, panel II), a
methoxy-substituted compound, was crystallized and selected
as a representative of the inactive molecules for the detailed
characterization. An ITC study with the RTK2 and p300 HAT
domainwas carried out. The enthalpy change corresponding to
the addition of the RTK2 to the p300HATdomain could not be
fitted to any binding model as apparent from the improbable
large values of standard errors of deviation (binding site n 
1.06  338, H  946  30,000 kcal/mol). It implies the
absence of any physical association of theOOH group substi-
tuted derivative, RTK2, with the p300 HAT domain (Fig. 6C).
This is in contrast with the strong interaction of RTK1 with the
p300 HAT domain. It was further supported from the docking
analysis of the HAT domain with RTK2, which does not show
the formation of a hydrogen bond or any other interaction with
RTK2 (Fig. 6D). These data argue for themechanistic and struc-
tural requirements of the OOH group to facilitate the p300
HAT inhibition.
We have earlier shown that several natural compounds, like
anacardic acid, curcumin, garcinol possess HAT inhibitory
activity. Interestingly, all these molecules are hydroxyl com-
pounds (Fig. 3B). The recently reported acetyltransferase inhib-
itor from a natural source, epigallocatechin 3-gallate, is also a
polyhydroxy compound (29). Anacardic acid has a single
hydroxyl group and is a potent and nonspecific inhibitor of
HATs. The amide derivative of anacardic acid, N-(4-chloro-3-
trifluoromethylphenyl)-2-ethoxybenzamide), instead of being
an inhibitor had HAT activation properties (30). A detailed
derivatization study of these amides revealed the importance of
the pentadecyl hydrocarbon chain and the presence of electro-
negative groups (CF3,Cl) at the para position for the HAT
activation (31). Curcumin, a natural p300-specific inhibitor
(32), also has two hydroxyl groups. Garcinol, a polyhydroxyl
benzophenone, which has three hydroxyl groups, is a potent
nonspecific HAT inhibitor (16) with high cellular permeability
and cellular toxicity. The cyclization of garcinol, through the
enolic hydroxyl group, yielded isogarcinol. Although isogarci-
nol retained the nonspecific HAT inhibitory activity, it was
found to be less potent (with higher IC50) as compared with
garcinol. The 14-monomethyl-substituted derivative of isogar-
cinol, LTK14, has a single hydroxyl group (17). This derivative
is a specific inhibitor of p300 and is almost nontoxic in nature.
However, LTK14 is a less potent inhibitor in comparison with
garcinol. This raises the possibility that multiple hydroxyl
groups in garcinol might be responsible for its potent HAT
inhibition ability. In agreement with our present finding, the
disubstitution of isogarcinol yielded compounds (devoid of any
hydroxyl groups) that could not inhibit the HAT activity. The
only exception is the methylsulfonyl-disubstituted isogarcinol
(LTK19), which was also found to be a p300-specific inhibitor
(17). However, the similar functional group substitution in
RTK1 did not show any inhibitory activity (Fig. 6A, lane 9).
In summary, we have identified a small molecule inhibitor of
the KAT, p300, from a natural source, which offered the oppor-
tunity to identify the chemical entity responsible for the inhibi-
tion of theKATactivity. All the natural KAT inhibitors (specific
and nonspecific) discovered so far possess a hydroxyl group.
We have shown that substitution of a single hydroxyl group
with any functional group (see Scheme I) present in plumbagin/
RTK1 completely ceases its ability to inhibit the KAT activity.
These data suggest that possibly the hydroxyl group-mediated
interaction of RTK1 with p300 could be essential for the inhi-
bition of acetyltransferase activity, as hypothesized previously
(33). This presumption could be general and might be one of
the mechanisms associated with HAT inhibition by these
inhibitors. Interestingly, in the p300 minimal HAT domain, a
novel site, Lys-1358, has been identified that is essential for the
acetyltransferase activity of p300. This residue is not a part of
the catalytic site nor the activation loop as suggested earlier
(28), yet it regulates the enzyme function. The exact role of this
residue needs to be characterized. Furthermore, the interaction
of the other p300 HAT inhibitors with this critical residue also
needs to be investigated. Plumbagin has been reported to sup-
press NF-B activation leading to the potentiation of apoptosis
(23). Because the process of NF-B activation requires p300-
mediated acetylation of the p65 subunit of NF-B, the suppres-
sion observed could be due to the p300-specific inhibition in
the physiological condition. Although plumbagin is a putative
anticancer agent (19–22), its major limitation for use as thera-
peutic molecule could be the cellular toxicity. Synthesis of effi-
cient nontoxic p300-specific KAT inhibitors, with an intact
hydroxyl group, could be highly useful both as a therapeutic as
well as a biological tool for modulating acetyltransferase func-
tion. However, we hope that these data could be highly useful in
designing therapeutically favorable novel acetyltransferase
inhibitors from the natural compound.
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